EUVIMEDEUVIMED entdecken
Fallbericht

Retrospective RNA Sequencing Reclassifies a Historical t (5;12) Eosinophilic Neoplasm From Presumed PDGFRB Rearrangement to ETV6::ACSL6

Frédéric Lambert iD, Rafael Fernandez Carazo, Benjamin Koopmansch iD, Elisa Dardenne iD, Pierre Sidon, Gaëlle Vertenoeil, Pierre Heimann

Genes, Chromosomes and Cancer · 2026-10 · 65 (10)

DOI: 10.1002/gcc.70178 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 07.10.2026. Verfasst von Frédéric Lambert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Human Genetics and Department of Laboratory Medicine, University Hospital of Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ets, Translocation, Genetic, Receptor, Platelet-Derived Growth Factor beta, Repressor Proteins. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Fonds Léon Fredericq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The molecular interpretation of eosinophilic neoplasms harboring t (5;12) may be challenging because cytogenetic breakpoint assignments can suggest a PDGFRB rearrangement without identifying the underlying fusion. We retrospectively investigated a woman with a chronic eosinophilic myeloid neoplasm initially investigated in 2002, in whom a subsequent t (5;12)(q31 ~ q33;p13) raised suspicion of PDGFRB involvement. Contemporary molecular investigations failed to identify the rearrangement, and an empiric trial of imatinib produced no meaningful hematologic response. Seventeen years later, blast transformation was accompanied by persistence of t (5;12) and acquisition of del(9)(q22). Fluorescence in situ hybridization demonstrated ETV6 rearrangement but no PDGFRB break‐apart pattern, indicating en bloc translocation of the PDGFRB locus. Targeted RNA sequencing of archived RNA extracted from cryopreserved peripheral blood cells collected in 2004 subsequently identified a strong‐evidence ETV6::ACSL6 fusion joining exon 2 of ETV6 to exon 2 of ACSL6 , supported by 1847 reads and 218 unique start sites. Targeted myeloid DNA sequencing detected no mutation within the regions analyzed. Identification of ETV6::ACSL6 shifted the biological interpretation away from presumed constitutive tyrosine kinase activation toward a proposed cytokine regulatory rewiring involving the 5q31 cytokine locus, consistent with published experimental evidence and the absence of response to imatinib. This case illustrates how contemporary RNA‐based fusion detection can resolve a historically uncharacterized structural rearrangement and refine biological interpretation and therapeutic expectations, while documenting an unusually prolonged natural history of an ETV6::ACSL6 ‐associated eosinophilic myeloid neoplasm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-etsTranslocation, GeneticReceptor, Platelet-Derived Growth Factor betaRepressor ProteinsHypereosinophilic SyndromeOncogene Proteins, FusionHumansETS Translocation Variant 6 ProteinFemaleChromosomes, Human, Pair 5Chromosomes, Human, Pair 12Sequence Analysis, RNAmRNA Cleavage and Polyadenylation Factors

Stichwörter der Autor:innen

ETV6::ACSL6CEL‐NOSchronic eosinophilic leukemiadiagnosishypereosinophiliahypereosinophilic syndromeimatinibmolecular resolutiont(5;12)targeted RNA sequencing

Substanzen

ETS Translocation Variant 6 ProteinProto-Oncogene Proteins c-etsPDGFRB protein, humanReceptor, Platelet-Derived Growth Factor betaRepressor ProteinsOncogene Proteins, FusionmRNA Cleavage and Polyadenylation Factors

Autor:innen und Institutionen

  • Center for Human Genetics and Department of Laboratory Medicine, University Hospital of Liège, Liège, Belgium.
  • Department of Laboratory Medicine, Cytogenetics Laboratory, Free University of Brussels, LHUB-ULB and Jules Bordet Institute, Anderlecht, Belgium.
  • Department of Hematology, University Hospital of Liège, Liège, Belgium.
  • Department of Laboratory Medicine, Hematology Laboratory, Free University of Brussels, LHUB-ULB and Jules Bordet Institute, Anderlecht, Belgium.

ORCID-Profile: Frédéric Lambert, Benjamin Koopmansch, Elisa Dardenne

Förderung

  • Fonds Léon Fredericq

Zitieren

APA

Lambert, F., Carazo, R. F., Koopmansch, B., Dardenne, E., Sidon, P., Vertenoeil, G., & Heimann, P. (2026). Retrospective RNA Sequencing Reclassifies a Historical t (5;12) Eosinophilic Neoplasm From Presumed PDGFRB Rearrangement to ETV6::ACSL6. Genes, Chromosomes and Cancer, 65(10). https://doi.org/10.1002/gcc.70178

Vancouver

Lambert F, Carazo RF, Koopmansch B, Dardenne E, Sidon P, Vertenoeil G, et al. Retrospective RNA Sequencing Reclassifies a Historical t (5;12) Eosinophilic Neoplasm From Presumed PDGFRB Rearrangement to ETV6::ACSL6. Genes, Chromosomes and Cancer. 2026;65(10). doi:10.1002/gcc.70178

BibTeX
@article{Lambert2026,
  author = {Lambert, Frédéric and Carazo, Rafael Fernandez and Koopmansch, Benjamin and Dardenne, Elisa and Sidon, Pierre and Vertenoeil, Gaëlle and Heimann, Pierre},
  title = {Retrospective RNA Sequencing Reclassifies a Historical t (5;12) Eosinophilic Neoplasm From Presumed PDGFRB Rearrangement to ETV6::ACSL6},
  journal = {Genes, Chromosomes and Cancer},
  year = {2026},
  volume = {65},
  number = {10},
  doi = {10.1002/gcc.70178}
}
Kostenlos starten →